BTAI
Price
$0.34
Change
-$0.01 (-2.86%)
Updated
Jan 17 closing price
Capitalization
17.07M
47 days until earnings call
CRDF
Price
$3.45
Change
+$0.05 (+1.47%)
Updated
Jan 17 closing price
Capitalization
229.51M
40 days until earnings call
Ad is loading...

BTAI vs CRDF

Header iconBTAI vs CRDF Comparison
Open Charts BTAI vs CRDFBanner chart's image
BioXcel Therapeutics
Price$0.34
Change-$0.01 (-2.86%)
Volume$896.02K
Capitalization17.07M
Cardiff Oncology
Price$3.45
Change+$0.05 (+1.47%)
Volume$1.28M
Capitalization229.51M
BTAI vs CRDF Comparison Chart
Loading...
BTAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BTAI vs. CRDF commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BTAI is a Hold and CRDF is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (BTAI: $0.34 vs. CRDF: $3.45)
Brand notoriety: BTAI and CRDF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BTAI: 86% vs. CRDF: 51%
Market capitalization -- BTAI: $17.07M vs. CRDF: $229.51M
BTAI [@Biotechnology] is valued at $17.07M. CRDF’s [@Biotechnology] market capitalization is $229.51M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BTAI’s FA Score shows that 0 FA rating(s) are green whileCRDF’s FA Score has 0 green FA rating(s).

  • BTAI’s FA Score: 0 green, 5 red.
  • CRDF’s FA Score: 0 green, 5 red.
According to our system of comparison, CRDF is a better buy in the long-term than BTAI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BTAI’s TA Score shows that 3 TA indicator(s) are bullish while CRDF’s TA Score has 2 bullish TA indicator(s).

  • BTAI’s TA Score: 3 bullish, 6 bearish.
  • CRDF’s TA Score: 2 bullish, 3 bearish.
According to our system of comparison, CRDF is a better buy in the short-term than BTAI.

Price Growth

BTAI (@Biotechnology) experienced а -8.83% price change this week, while CRDF (@Biotechnology) price change was -4.43% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

BTAI is expected to report earnings on May 12, 2025.

CRDF is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRDF($230M) has a higher market cap than BTAI($17.1M). BTAI YTD gains are higher at: -7.997 vs. CRDF (-20.507). CRDF has higher annual earnings (EBITDA): -46M vs. BTAI (-56.15M). CRDF has more cash in the bank: 57.7M vs. BTAI (40.4M). CRDF has less debt than BTAI: CRDF (1.69M) vs BTAI (105M). BTAI has higher revenues than CRDF: BTAI (2.28M) vs CRDF (688K).
BTAICRDFBTAI / CRDF
Capitalization17.1M230M7%
EBITDA-56.15M-46M122%
Gain YTD-7.997-20.50739%
P/E RatioN/AN/A-
Revenue2.28M688K331%
Total Cash40.4M57.7M70%
Total Debt105M1.69M6,228%
FUNDAMENTALS RATINGS
BTAI vs CRDF: Fundamental Ratings
BTAI
CRDF
OUTLOOK RATING
1..100
7264
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
68
Overvalued
PROFIT vs RISK RATING
1..100
10086
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
9541
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRDF's Valuation (68) in the null industry is in the same range as BTAI (82) in the Biotechnology industry. This means that CRDF’s stock grew similarly to BTAI’s over the last 12 months.

CRDF's Profit vs Risk Rating (86) in the null industry is in the same range as BTAI (100) in the Biotechnology industry. This means that CRDF’s stock grew similarly to BTAI’s over the last 12 months.

CRDF's SMR Rating (98) in the null industry is in the same range as BTAI (100) in the Biotechnology industry. This means that CRDF’s stock grew similarly to BTAI’s over the last 12 months.

CRDF's Price Growth Rating (41) in the null industry is somewhat better than the same rating for BTAI (95) in the Biotechnology industry. This means that CRDF’s stock grew somewhat faster than BTAI’s over the last 12 months.

CRDF's P/E Growth Rating (100) in the null industry is in the same range as BTAI (100) in the Biotechnology industry. This means that CRDF’s stock grew similarly to BTAI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BTAICRDF
RSI
ODDS (%)
Bearish Trend 11 days ago
86%
N/A
Stochastic
ODDS (%)
Bearish Trend 11 days ago
86%
Bullish Trend 11 days ago
90%
Momentum
ODDS (%)
Bullish Trend 11 days ago
83%
Bearish Trend 11 days ago
82%
MACD
ODDS (%)
Bullish Trend 11 days ago
82%
Bearish Trend 11 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 11 days ago
83%
Bearish Trend 11 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 11 days ago
84%
Bullish Trend 11 days ago
90%
Advances
ODDS (%)
Bullish Trend 13 days ago
82%
N/A
Declines
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 11 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 11 days ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 11 days ago
90%
N/A
View a ticker or compare two or three
Ad is loading...
BTAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ASVDX10.950.08
+0.74%
American Century Small Cap Value R6
CSIFX44.940.27
+0.60%
Calvert Balanced A
CICGX9.790.04
+0.41%
AB Concentrated International Growth C
UBPIX11.95N/A
N/A
ProFunds UltraLatin America Inv
GMHPX12.55N/A
N/A
Goldman Sachs Rising Dividend Gr P

BTAI and

Correlation & Price change

A.I.dvisor indicates that over the last year, BTAI has been loosely correlated with ORMP. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if BTAI jumps, then ORMP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BTAI
1D Price
Change %
BTAI100%
-0.52%
ORMP - BTAI
44%
Loosely correlated
-1.72%
AXON - BTAI
42%
Loosely correlated
+1.37%
INO - BTAI
39%
Loosely correlated
+8.90%
SYBX - BTAI
39%
Loosely correlated
+0.69%
IGMS - BTAI
38%
Loosely correlated
-3.28%
More

CRDF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRDF has been loosely correlated with MDGL. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CRDF jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRDF
1D Price
Change %
CRDF100%
+1.47%
MDGL - CRDF
46%
Loosely correlated
+7.64%
ORMP - CRDF
39%
Loosely correlated
-1.72%
CMRX - CRDF
37%
Loosely correlated
-3.01%
VRPX - CRDF
34%
Loosely correlated
-2.06%
BTAI - CRDF
34%
Loosely correlated
-0.52%
More